文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

在乌干达,接受抗逆转录病毒疗法的艾滋病毒/艾滋病患者中,低水平病毒血症与随后的病毒未抑制之间的关联。

The association between low-level viraemia and subsequent viral non-suppression among people living with HIV/AIDS on antiretroviral therapy in Uganda.

机构信息

Department of Epidemiology and Biostatistics, School of Public Health, Makerere University College of Health Sciences, Kampala, Uganda.

Department of National Health Laboratory Services, Ministry of Health, Kampala Uganda.

出版信息

PLoS One. 2023 Jan 13;18(1):e0279479. doi: 10.1371/journal.pone.0279479. eCollection 2023.


DOI:10.1371/journal.pone.0279479
PMID:36638086
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9838846/
Abstract

BACKGROUND: Uganda's efforts to end the HIV epidemic by 2030 are threatened by the increasing number of PLHIV with low-level viraemia (LLV). We conducted a study to determine the prevalence of LLV and the association between LLV and subsequent viral non-suppression from 2016 to 2020 among PLHIV on ART in Uganda. METHOD: This was a retrospective cohort study, using the national viral load (VL) program data from 2016 to 2020. LLV was defined as a VL result of at least 50 copies/ml, but less than 1,000 copies/ml. Multivariable logistic regression was used to determine the factors associated with LLV, and cox proportional hazards regression model was used to determine the association between LLV and viral non-suppression. RESULTS: A cohort of 17,783 PLHIV, of which 1,466 PLHIV (8.2%) had LLV and 16,317 (91.8%) had a non-detectable VL was retrospectively followed from 2016 to 2020. There were increasing numbers of PLHIV with LLV from 2.0% in 2016 to 8.6% in 2020; and LLV was associated with male sex, second line ART regimen and being of lower age. 32.5% of the PLHIV with LLV (476 out of 1,466 PLHIV) became non-suppressed, as compared to 7.7% of the PLHIV (1,254 out of 16,317 PLHIV) with a non-detectable viral load who became non-suppressed during the follow-up period. PLHIV with LLV had 4.1 times the hazard rate of developing viral non-suppression, as compared to PLHIV with a non-detectable VL (adjusted hazard ratio was 4.1, 95% CI: 3.7 to 4.7, p < 0.001). CONCLUSION: Our study indicated that PLHIV with LLV increased from 2.0% in 2016 to 8.6% in 2020, and PLHIV with LLV had 4.1 times the hazard rate of developing viral non-suppression, as compared to PLHIV with a non-detectable VL. Hence the need to review the VL testing algorithm and also manage LLV in Uganda.

摘要

背景:乌干达力争在 2030 年终结艾滋病毒流行,但不断增加的艾滋病毒感染者(PLHIV)出现低水平病毒血症(LLV),这一目标受到威胁。本研究旨在确定 2016 年至 2020 年期间,乌干达接受抗逆转录病毒治疗(ART)的 PLHIV 中 LLV 的流行率,以及 LLV 与随后病毒抑制失败之间的关联。

方法:这是一项回顾性队列研究,使用了 2016 年至 2020 年全国病毒载量(VL)监测项目的数据。将 VL 至少为 50 拷贝/ml 但小于 1000 拷贝/ml 的情况定义为 LLV。多变量逻辑回归用于确定与 LLV 相关的因素,Cox 比例风险回归模型用于确定 LLV 与病毒抑制失败之间的关联。

结果:从 2016 年至 2020 年,共回顾性随访了 17783 例 PLHIV,其中 1466 例(8.2%)存在 LLV,16317 例(91.8%)VL 不可检测。PLHIV 中 LLV 的比例从 2016 年的 2.0%逐渐增加到 2020 年的 8.6%;LLV 与男性、二线 ART 方案和较低年龄相关。1466 例 LLV 患者中有 32.5%(476 例)发生病毒抑制失败,而 16317 例 VL 不可检测的患者中只有 7.7%(1254 例)在随访期间发生病毒抑制失败。与 VL 不可检测的 PLHIV 相比,LLV 的 PLHIV 发生病毒抑制失败的危险率高 4.1 倍(调整后的危险比为 4.1,95%CI:3.7 至 4.7,p < 0.001)。

结论:本研究表明,PLHIV 中 LLV 的比例从 2016 年的 2.0%增加到 2020 年的 8.6%,而与 VL 不可检测的 PLHIV 相比,LLV 的 PLHIV 发生病毒抑制失败的危险率高 4.1 倍。因此,有必要审查乌干达的 VL 检测算法,并对 LLV 进行管理。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d13d/9838846/59a40047e051/pone.0279479.g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d13d/9838846/30f71aa1e409/pone.0279479.g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d13d/9838846/1ea1da2da038/pone.0279479.g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d13d/9838846/59a40047e051/pone.0279479.g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d13d/9838846/30f71aa1e409/pone.0279479.g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d13d/9838846/1ea1da2da038/pone.0279479.g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d13d/9838846/59a40047e051/pone.0279479.g003.jpg

相似文献

[1]
The association between low-level viraemia and subsequent viral non-suppression among people living with HIV/AIDS on antiretroviral therapy in Uganda.

PLoS One. 2023

[2]
Effectiveness of intensive adherence counselling in achieving an undetectable viral load among people on antiretroviral therapy with low-level viraemia in Uganda.

HIV Med. 2024-2

[3]
Association of low-level viremia with mortality among people living with HIV on antiretroviral therapy in Dehong, Southwest China: A retrospective cohort study.

HIV Med. 2023-1

[4]
High viral suppression rates among PLHIV on dolutegravir who had an initial episode of viral non-suppression in Uganda September 2020-July 2021.

PLoS One. 2024

[5]
Outcomes of persistent low-level viremia among HIV patients on antiretroviral therapy: A prospective cohort study.

HIV Med. 2022-3

[6]
Low-Level Viremia among Adults Living with HIV on Dolutegravir-Based First-Line Antiretroviral Therapy Is a Predictor of Virological Failure in Botswana.

Viruses. 2024-5-1

[7]
Low-level HIV viraemia during antiretroviral therapy: Longitudinal patterns and predictors of viral suppression.

HIV Med. 2024-1

[8]
Impact of low-level viraemia on virological failure among Asian children with perinatally acquired HIV on first-line combination antiretroviral treatment: a multicentre, retrospective cohort study.

J Int AIDS Soc. 2020-7

[9]
Factors associated with high-risk low-level viremia leading to virologic failure: 16-year retrospective study of a Chinese antiretroviral therapy cohort.

BMC Infect Dis. 2020-2-17

[10]
Factors associated with low-level viraemia in people with HIV starting antiretroviral therapy: A Swedish observational study.

PLoS One. 2022

引用本文的文献

[1]
A Guide to the Evolving Clinical Landscape of Low-Level Viremia Among Persons with HIV in the Modern Treatment Era.

Curr HIV/AIDS Rep. 2025-6-26

[2]
Impact of low-level viremia on HIV non-viral load suppression in low and middle-income countries.

Ann Med Surg (Lond). 2025-4-10

[3]
Low-level viraemia as a risk factor for virologic failure in children and adolescents living with HIV on antiretroviral therapy in Tanzania: a multicentre, retrospective cohort study.

J Int AIDS Soc. 2025-5

[4]
Associations of First-Year Low-Level Viremia with Subsequent Viral Non-Suppression in People Living with HIV on Antiretroviral Therapy - Dehong Dai and Jingpo Autonomous Prefecture, Yunnan Province, China, 2008-2021.

China CDC Wkly. 2025-1-10

[5]
Prevalence of drug resistance mutations in low-level viremia patients under antiretroviral therapy in Southwestern China: a cross-sectional study.

J Antimicrob Chemother. 2025-4-2

[6]
HIV-1 Low-Level Viremia Predicts Viral Failure in Participants on Antiretroviral Therapy in the Swiss HIV Cohort Study.

Clin Infect Dis. 2025-8-1

[7]
Association between differentiated HIV care delivery model and low-level viremia among people living with HIV in Rwanda.

AIDS Res Ther. 2024-11-1

[8]
Consequences of low-level viremia among women with HIV in the United States.

AIDS. 2024-11-1

[9]
Predictors of Viral Suppression among Adults Living with HIV/AIDS in Nigeria: A Retrospective Chart Review.

Ann Afr Med. 2024-4-1

[10]
Geospatial and temporal mapping of detectable HIV-1 viral loads amid dolutegravir rollout in KwaZulu-Natal, South Africa.

PLOS Glob Public Health. 2024-5-28

本文引用的文献

[1]
Barriers and Facilitating Factors to HIV Treatment Among Men in a High-HIV-Burdened District in KwaZulu-Natal, South Africa: A Qualitative Study.

Am J Mens Health. 2022

[2]
Risk factors for sustained virological non-suppression among children and adolescents living with HIV in Zimbabwe and Malawi: a secondary data analysis.

BMC Pediatr. 2022-6-11

[3]
Factors associated with virological non-suppression among HIV-positive children receiving antiretroviral therapy at the Joint Clinical Research Centre in Lubowa, Kampala Uganda.

PLoS One. 2021

[4]
Optimizing viral load suppression in Kenyan children on antiretroviral therapy (Opt4Kids).

Contemp Clin Trials Commun. 2020-10-27

[5]
Predictors of mortality among adult people living with HIV/AIDS on antiretroviral therapy at Suhul Hospital, Tigrai, Northern Ethiopia: a retrospective follow-up study.

J Health Popul Nutr. 2019-11-29

[6]
Twenty Years Of Antiretroviral Therapy For People Living With HIV: Global Costs, Health Achievements, Economic Benefits.

Health Aff (Millwood). 2019-7

[7]
HIV virologic failure and its predictors among HIV-infected adults on antiretroviral therapy in the African Cohort Study.

PLoS One. 2019-2-5

[8]
Factors associated with recent unsuppressed viral load in HIV-1-infected patients in care on first-line antiretroviral therapy in South Africa.

Int J STD AIDS. 2018-5

[9]
Selecting a viral load threshold for routine monitoring in resource-limited settings: optimizing individual health and population impact.

J Int AIDS Soc. 2017-11

[10]
Effect of HIV-1 low-level viraemia during antiretroviral therapy on treatment outcomes in WHO-guided South African treatment programmes: a multicentre cohort study.

Lancet Infect Dis. 2017-11-17

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索